HLA-B: A Promising Drug Target / Biomarker (G3106)

Target Name: HLA-B

NCBI ID: G3106

HLA-B

HLA-B: A Promising Drug Target / Biomarker

HLA-B is a protein that is expressed in the human immune system, specifically in T cells. It is a key regulator of immune responses and has been linked to various autoimmune diseases. Despite its importance, little is known about HLA-B and its potential as a drug target or biomarker. In this article, we will explore the biology and potential applications of HLA-B as a drug target and biomarker.

Background

HLA-B is a member of the major histocompatibility complex (MHC) family, which is a group of genes that encode the antigens that are recognized by the immune system. HLA-B is a type-I transmembrane protein that is expressed in most tissues of the body, including the brain, spleen, skin, and gastrointestinal tract. It is involved in the immune response by regulating the movement of immune cells into the site of an infection or inflammation.

HLA-B has been implicated in a number of autoimmune diseases, including rheumatoid arthritis, Crohn's disease, and multiple sclerosis. These diseases are characterized by the immune system attacking the body's own tissues, leading to inflammation and damage. In addition, HLA-B has also been linked to cancer development.

Despite these potential connections, much is still not known about HLA-B and its role in the immune system. One reason is that the research on HLA-B has been limited due to its complex structure and the difficulty of studying it in living organisms. Another reason is that HLA-B is a protein that is expressed in many different cell types, making it difficult to isolate and study it in isolation.

HLA-B's Potential as a Drug Target

One potential way to study HLA-B is as a drug target. By inhibiting the activity of HLA-B in the immune system, researchers may be able to treat autoimmune diseases and cancer. One way to do this is through the use of small molecules, such as drugs that bind to specific HLA-B receptors. These drugs could be used to treat autoimmune diseases by reducing the activity of HLA-B in the immune system.

Another potential way to study HLA-B is as a biomarker. HLA-B is a protein that is expressed in many different cell types, making it difficult to study in isolation. By using techniques such as mass spectrometry, researchers have been able to identify potential biomarkers for HLA-B that may be useful for tracking the progress of an immune response. These biomarkers could potentially be used to diagnose and monitor immune-related diseases.

HLA-B's Potential as a Biomarker

HLA-B is a protein that is expressed in many different cell types, making it difficult to study in isolation. By using techniques such as mass spectrometry, researchers have been able to identify potential biomarkers for HLA-B that may be useful for tracking the progress of an immune response. These biomarkers could potentially be used to diagnose and monitor immune-related diseases.

One potential biomarker for HLA-B is the level of HLA-B expression in the immune cells. Researchers have used techniques such as flow cytometry to measure the level of HLA-B expression in different immune cell types, such as T cells and B cells. They have found that the level of HLA-B expression in these cells is closely correlated with the activity of the immune system. This suggests that HLA-B may be a useful biomarker for tracking the effectiveness of immunotherapy

Protein Name: Major Histocompatibility Complex, Class I, B

Functions: Antigen-presenting major histocompatibility complex class I (MHCI) molecule. In complex with B2M/beta 2 microglobulin displays primarily viral and tumor-derived peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-B-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected or transformed cells (PubMed:25808313, PubMed:29531227, PubMed:9620674, PubMed:23209413). May also present self-peptides derived from the signal sequence of secreted or membrane proteins, although T cells specific for these peptides are usually inactivated to prevent autoreactivity (PubMed:7743181, PubMed:18991276). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (PubMed:29531227, PubMed:9620674, PubMed:24600035). Typically presents intracellular peptide antigens of 8 to 13 amino acids that arise from cytosolic proteolysis via constitutive proteasome and IFNG-induced immunoproteasome (PubMed:23209413). Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9 (PubMed:25808313, PubMed:29531227)

The "HLA-B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HLA-B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets